General Applications

Liquidia Technologies is a privately-held clinical stage company focused on advancing vaccines and therapeutics that leverage the PRINT^®technology for design and manufacture of engineered particles. The PRINT^®technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process. In addition to its own products, Liquidia licenses its PRINT^®particle technology and its GMP manufacturing capabilities to support proprietary programs advanced by collaborators.

About Liquidia:

• We are committed to advancing precisely engineered products that profoundly impacts the lives of patients.
• Liquidia is proud of its cultural values and strives for excellence and innovation in everything that we do.
• Liquidia was founded in 2004 on the discoveries of Professor Joseph DeSimone at UNC, Chapel Hill
• We are located in Research Triangle Park, North Carolina.
• For additional information, please visit www.liquidia.com